# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-27T17:03:18.916460

---

**Idea Fidelity**

The paper broadly adheres to the original manifest. It investigates whether state-mandated healthcare workplace violence prevention (WVP) programs reduce OSHA-reported injuries, uses OSHA ITA 300A data aggregated to the state-year level, and exploits staggered state-level adoptions with the Callaway–Sant’Anna (CS) estimator. However, two elements of the manifest are underutilized. First, the manifest highlighted use of OIICS violence-event codes from the OSHA Case Detail data (2023+), which could allow a more direct measure of violence-specific incidents; the paper does not analyze these data or explain why they were omitted. Second, the manifest proposed placebo tests using non-healthcare establishments and non-violence injury types; the paper conducts the former but not the latter. Clarifying these omissions would strengthen fidelity.

---

**Summary**

The paper evaluates state healthcare workplace violence prevention mandates adopted between 2017 and 2023 using OSHA ITA 300A data and a staggered Callaway–Sant’Anna difference-in-differences design. It finds that the mandates have no detectable effect on days-away-from-work (DAFW) injury rates once the anomalous 2023 data year is excluded, while the positive effect in the full sample is attributed to state-specific trends rather than the policy. Robustness checks, including placebo tests with non-healthcare establishments and specifications with state trends, support the conclusion that mandating prevention plans yields compliance without preventing injuries.

---

**Essential Points**

1. **Interpretation of the Preferred Sample**  
   The paper treats the exclusion of 2023 as yielding the “preferred” specification because the 2023 data are allegedly anomalous. Yet this raises concerns about post-treatment selection: if treated states adopted mandates through 2023, excluding the latest year also removes the most relevant post-treatment observations, potentially biasing estimates downward. The paper should provide stronger evidence that 2023 is unusable (e.g., diagnostic plots of reporting lags, comparison to historical revisions) and demonstrate that including 2023 but addressing its peculiarities (e.g., modeling a common shock) does not materially change the inference. Otherwise, the preferred null may reflect sample trimming rather than the absence of effects.

2. **Measurement of Violence-Specific Outcomes**  
   The identification question is whether WVP mandates reduce workplace violence, yet the outcome is DAFW injury rate, which includes all injuries and may be only weakly related to violence incidents. The manifest mentioned availability of OSHA Case Detail data with OIICS violence codes, but the paper does not use them. Without a more direct measure of violence, it is unclear whether the mandates had no effect on violence specifically or whether violence incidents were masked by broader injury fluctuations. The authors should either incorporate the violence-specific case detail data (even if shorter panel) or argue rigorously why DAFW is a valid proxy and why violence-specific data are unnecessary.

3. **Parallel Trends and Event Study Interpretation**  
   The event study (Table 3) shows a large, statistically significant pre-trend at $e=-1$ and growing post-trends attributable to 2023, yet the paper still claims parallel trends. The placebo evidence that non-healthcare establishments exhibit similar upward trends raises doubts about whether treated and control states were comparable, especially in the immediate pre-period. Additional diagnostics (e.g., pre-trend tests, permutation-based inference) and a discussion of why the $e=-1$ spike should not invalidate identification are needed. Without resolving this, it is hard to accept the causal interpretation even in the preferred sample.

If these issues cannot be satisfactorily addressed, the paper should not proceed.

---

**Suggestions**

1. **Leverage Violence-specific Case Detail Data**  
   The manifest noted access to OSHA Case Detail data with OIICS event codes starting in 2023. Even though the panel is shorter, analyzing this data could provide a more direct test of whether mandates reduce violence-specific incidents. If sample size is too small, consider stacking the case-level data to construct a difference-in-differences at the establishment or injury level for the subset of states/years with violence coding. Alternatively, aggregate the case detail violence counts by state-year and use them as a secondary outcome. At a minimum, discuss why this data source was not used or was infeasible, noting limitations such as short time coverage or changes in reporting requirements.

2. **Assess Reporting vs. Prevention Effects**  
   The mandates explicitly require incident reporting, so any evaluation must disentangle whether observed changes (or lack thereof) reflect reporting changes rather than actual incidence. While the paper acknowledges the reporting concern qualitatively, it does not attempt to quantify it. Consider exploiting variation in reporting requirements (e.g., mandate features related to incident logging) or using event codes that differentiate between violence and other injuries to test whether reporting intensity increased. You could also examine whether less severe incident types (which mandates might inflate via reporting) changed differently than severe ones. This would strengthen the interpretation that the null reflects real prevention outcomes rather than offsetting reporting effects.

3. **Clarify the Role of 2023 Observations**  
   The paper attributes the positive full-sample estimate to a 2023 anomaly but does not show systematic evidence of reporting issues beyond stating the data cover submissions “through 12-31-2024.” Present concrete diagnostics: compare aggregate injury counts or reporting rates in 2023 to past trends, examine whether certain states’ 2023 submissions diverge dramatically from their own trends, or use metadata from OSHA about lagged submissions. If possible, adjust for the anomaly (e.g., include a 2023 shock dummy or reweight observations) rather than drop the year entirely, and compare results. This will show whether the null is robust to reasonable treatments of 2023 and not an artifact of dropping data.

4. **Elaborate on Treatment Coding and Timing**  
   The treatment coding lumps states with different enforcement regimes and implementation lags into a single adoption date. Discuss whether effective dates align with actual enforcement or merely statutory passage. Consider robustness checks that allow for implementation lags (e.g., define treatment as starting one year after the statute takes effect) or that exploit heterogeneity in mandate strength (e.g., training-only versus training-plus-design features). Sensitivity to these choices would reassure readers that the estimated null is not driven by measurement error in the treatment variable.

5. **Provide More Informative Event Studies**  
   The event-study table shows wide confidence intervals and a large negative coefficient at $e=-1$ that could indicate violation of parallel trends. Plotting the coefficients with confidence intervals and overlaying the estimates excluding 2023 would help readers gauge pre-trend violations. You might also estimate the CS event study on the preferred sample (2016–2022) to demonstrate whether the pre-trends flatten out when 2023 is omitted. If the $e=-1$ spike disappears in the trimmed sample, explain why or how it connects to 2023-related shocks.

6. **Revisit the Triple-Difference Strategy**  
   The triple-difference estimate remains positive and marginally significant even when the preferred specification is null, raising questions about the sources of this difference. Provide more detail on the non-healthcare control group: what industries does it include, and do these industries share similar trends with healthcare? It may be that the placebo failure stems from selecting a control group that experienced its own policy shocks. Consider testing other placebo sectors (e.g., manufacturing) or constructing a synthetic control from non-healthcare units that mimic treated healthcare pre-trends. This would clarify whether the DDD is valid and whether its positive estimate truly contradicts the CS result.

7. **Emphasize Mechanism Discussion with Data Support**  
   The discussion section argues for “compliance without prevention,” but this is speculative. Incorporate any available data (e.g., from OSHA inspection records or state reports) that speak to compliance behaviors — for example, whether mandates led to more plans/training but not to operational changes. Alternatively, cite qualitative studies documenting similar compliance equilibria, making it clear that the interpretation is suggestive rather than proven. This will help policymakers understand whether the null stems from ineffective compliance requirements or deeper structural constraints.

8. **Address Sampling Variation Across States**  
   Summary statistics show treated states tend to be larger with more establishments than controls. While the CS estimator handles weighting, consider showing that results are robust to weighting treated and control states equally (e.g., using state-level weights or dropping the largest states). This would help ensure that the null is not driven by a few large states with atypical trends.

9. **Discuss Power and Meaningful Effect Sizes**  
   The paper claims that it can rule out effects larger than about one DAFW case per 100 workers. Elaborate on this by presenting minimum detectable effect calculations based on sample size and variance, and relate them to policy-relevant benchmarks (e.g., how many assaults occur in a typical hospital). This contextualization would help readers interpret the null as substantive rather than simply statistically insignificant.

By addressing these suggestions, the paper would present a more convincing causal story and provide clearer guidance to policymakers on the limits of mandate-style regulation.
